Plasma lipid fractions in different HMGCR SNP genotypes Mean difference in plasma lipid fraction concentration(mmol/L) rs17238484 SNP genotype (T-control.

Slides:

Advertisements

Similar presentations

A GRADUATING RESEARCH PROJECT FOR THE BACHALOLIC DEGEES.

Advertisements

Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin Featured Article: Beverley Balkau, Philip D. Home, Maya Vincent,

Slide Source: Lipids Online Slide Library 56 healthy premenopausal obese women (aged 25–44 years) compared with 40 age-matched nonobese.

Hepatitis web study Hepatitis web study Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Phase 2b Treatment Naïve and Treatment Experienced.

Philip J. Barter, et al. Circulation 2011;124:

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.

Pharmacogenomics: Genotype specific response to a weight loss drug Paper by Hauner et al. Pharmacogenetics 2003; 13(8): Presented by: Payal Sipahimalani.

Diabetes Prevention Program (DPP)

Schematic of the single variant polymorphism (SNP) genotyping assay.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,

Tishkoff. Science Tishkoff. Science

Table 2. Changes in body composition, energy and water intake

RESULTS OF THE RIMONABANT IN OBESITY (RIO) PROGRAM AT 1 YEAR

Updates on Policy #38 Addressing Subjects with Non-Average Heights and Weights 2017 SWOG Fall Meeting BOG Siu Fun Wong, PharmD Co-Chair, Pharmaceutical.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Fig. 1. Effects of MD-2 promoter SNPs on transcription activity

Bertram et al. (2005) , NEJM, 352: Bertram et al. (2005) , NEJM, 352:

Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I

Table 1. General Characteristics of the Study Subjects

Genotype and Phenotype

Effect of Ma-Pi diet versus control diet on change in TNF-α, IL-6, CRP, BAP test, and IGF-1. Effect of Ma-Pi diet versus control diet on change in TNF-α,

Hajer GR et al. Atherosclerosis 2009;202:216-24

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

Finucane MM et al. Lancet 2011;377:557-67

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al.

Volume 63, Issue 5, Pages (May 2003)

Phase 2 Treatment Experienced (with Sofosbuvir and Ribavirin)

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

The correlation between visceral fat area (VFA) and body mass index (BMI) in patients with type 2 diabetes. The correlation between visceral fat area (VFA)

Exosomes transfected with obesity-associated miRNAs induce glucose intolerance dissociated from obesity. Exosomes transfected with obesity-associated miRNAs.

Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.

Results for HbA1c (A), severe or BG-confirmed symptomatic hypoglycemia (B), change in body weight (C), daily total insulin dose (D), FPG (E), and nine-point.

Glucose, insulin, and AGE levels during an OGC before and after RT

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

Arterial plasma glucose level and peripheral GIR in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with vehicle.

(A) Energy and (B) protein intake/day during hospitalisation and in follow-up. (A) Energy and (B) protein intake/day during hospitalisation and in follow-up.

Plasma growth hormone concentrations during a 65-min infusion of acyl ghrelin at 0.3, 0.9, or 1.5 nmol/kg/h, or saline. Plasma growth hormone concentrations.

Relationships between plasma NEFA concentrations and BMI in two cohorts. Relationships between plasma NEFA concentrations and BMI in two cohorts. Black.

Comparison of women carrying a male fetus and those carrying a female fetus, with respect to mean adjusted blood glucose levels during the OGTT (A), mean.

Sleep timing modifies the effect of MTNR1B variant rs on risk of T2D in MESA (n = 1,513). Sleep timing modifies the effect of MTNR1B variant rs

Prevalence of diabetes according to genotype and parental origin of alleles in American Indians. Prevalence of diabetes according to genotype and parental.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Chop deletion preserves β-cell function in P58IPK−/− mice.

Stratified analysis of the association between GDM and abdominal circumference (AC) >90th percentile at 28 wkGA. Stratified analysis of the association.

Plasma concentrations of glucose, insulin, C-peptide and glucagon observed in subjects with NFG/NGT, NFG/IGT, IFG/NGT, and IFG/IGT-D following ingestion.

The lack of effect of denatonium to stimulate insulin release in the absence of extracellular Ca2+ or in the presence of 10 μmol/l nitrendipine. The lack.

Mean (±SE) plasma glucose concentrations before, during, and after infusions of octreotide (with growth hormone) with saline (•), with insulin replacement.

Effect of cold exposure on determinants of glucose tolerance.

Food intake in response to central infusion of glucose (squares) or insulin (triangles) and in response to successive central infusion of insulin, insulin.

Insulin resistance and hepatic steatosis in ASKO mice.

Effects of Rosi treatment on ASKO mice.

Effects of berberine on in vivo metabolism in two animal models of insulin resistance. Effects of berberine on in vivo metabolism in two animal models.

High-fat diet–induced glucose intolerance is prevented in ghrelin knockout (Ghr-KO) mice. High-fat diet–induced glucose intolerance is prevented in ghrelin.

β-Cell–specific deletion of Phb2 renders mice diabetic.

Glycemic control and body weight over 52 weeks.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Allele-specific PCR by positioning the variant at the 3′ end of one primer Allele-specific PCR by positioning the variant at the 3′ end of one primer (A)

Scatterplot and LD map of the genotyped tagging SNPs along the TOX3/LOC region. Scatterplot and LD map of the genotyped tagging SNPs along the TOX3/LOC

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Effects of PCSK7 rs genotype and CHO diets on changes and reversion in fasting insulin levels and HOMA-IR during the 2-year intervention in white.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Plasma lipid fractions in different HMGCR SNP genotypes Mean difference in plasma lipid fraction concentration(mmol/L) rs SNP genotype (T-control or G alleles) TT (reference) Swerdlow et al., The Lancet 2014 GT vs TT GG vs TTPer G allele

Plasma glucose and insulin in different HMGCR SNP genotypes Swerdlow et al., The Lancet 2014 Difference in geometric mean of plasma glucose and plasma insulin (%) rs SNP genotype (T-control or G alleles) TT (reference) GT vs TT GG vs TTPer G allele

Bodyweight and BMI in different HMGCR SNP genotypes Swerdlow et al., The Lancet 2014 Mean difference in body weight (kg) rs SNP genotype (T-control or G alleles) TT (reference) GT vs TT GG vs TTPer G allele Mean difference in BMI (kg/m2)